Charlesson, LLC

Biotech · Private

Monoclonal antibody (2F1mab) that blocks LRP6 to inhibit Wnt pathway signaling in diabetic retinopathy

Claim this profile

Follows are private to you and power your alerts

Updated

Sector
Biotech
Total capital
$225K
Federal grants
$225K
1 award · 2015
Rank in peer group#254 of 392
Private capital raised
None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts
None on recordNo federal contract awards found.
Granted patents
0
2 pending

Capital timeline

2015FEDERAL ↑EQUITY ↓Cumulative $225K$225K
2015FEDERAL ↑EQUITY ↓Cumulative $225K$225K

Latest events

  • Federal grantHealth and Human S · Phase I · A Novel Therapeutic Antibody for Age-related Macular Degeneration$225K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 392 peers

Line = median

Biotech · Molecule

  • Federal grantsBelow median
  • Linked publications#6 · top 2%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 0 granted of 2
  • PendingSTAT3 Inhibitors For Treatment Of Hyperglycemia And Impaired Spatial VisionUSPTOApplication PCTUS2014036314
  • PendingThalidomide Analogs For Treating Vascular AbnormalitiesUSPTOApplication PCTUS2008066064

Recent research by its founders

  • Anti-biofouling Hydrogels: Surface Hydration, Classification, and Biomedical Applications20261 cites
  • Anesthetic State-Dependent Bidirectional Control of States of Consciousness via Heterogeneous Medial Septum to Ventral Tegmental Area Circuits under Sevoflurane in Mice20260 cites
  • Chain entanglement-stabilized injectable zwitterionic hydrogel for vitreous replacement and retinal tamponade20260 cites

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .